KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2).

Esther Natalie Oliva, Maria Cuzzola, Matteo Della Porta, Anna Candoni, Prassede Salutari, Giuseppe A Palumbo, Gianluigi Reda, Giuseppe Iannì, Matteo Zampini, Saverio D'Amico, Giovanni Tripepi, Debora Capelli, Caterina Alati, Maria Concetta Cannatà, Pasquale Niscola, Bianca Serio, Santina Barillà, Pellegrino Musto, Ernesto Vigna, Lorella Maria Antonia Melillo, Rocco Tripepi, Maria Elena Zannier, Yasuhito Nannya, Seishi Ogawa, Corrado Mammì

Int J Mol Sci 25(21) 11646

PMID39519198
PMCIDPMC11545844
DOI10.3390/ijms252111646
发表日期2024-11-09
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:已识别 KM 曲线,但未在图像中识别到 No. at risk 表,需人工复核正文或补充材料。
摘要

摘要

The achievement of complete remission (CR) is crucial for acute myeloid leukemia (AML) patients undertaking curative therapy, but relapse often occurs within months, highlighting the need for strategies to prolong disease-free survival (DFS). Our phase III study compared the efficacy and safety of azacitidine (AZA) to best supportive care (BSC) in elderly AML patients who achieved CR following intensive induction and consolidation therapy. This ancillary study (QOL-ONE Trans-2) evaluated biological changes in bone marrow using Next-Generation Sequencing (NGS). We analyzed baseline, randomization, and 6-month post-remission samples from 24 patients (median age of 71 and 12 males). High-throughput NGS targeted 350 myeloid malignancy-related genes, considering variants with a variant allele frequency ≥ 4%. At diagnosis, all patients had 5 to 17 (median = 10) mutations, with DNMT3A (42%), NPM1 (33%), and TET2 (33%) being most frequent. FANCA mutations in four patients were linked to a higher relapse risk (HR = 4.96, p = 0.02) for DFS at both 2 and 5 years. Further HLA-specific NGS analyses are ongoing to confirm these results and their therapeutic implications.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 3

Figure 3 Disease free survival up to 5 years in all randomized patients ( A ) and those stratified by unmutated (N = 20) and mutated (N = 4) FANCA genes ( B ) at diagnosis. DFS = disease-free survival.

A

DFS

Figure 3 · Panel A

complete 待 EXE 对齐 预期 1 条 已提取 1 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

DFS

Figure 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:short span曲线 2:short span
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Most frequently mutated genes of patients at diagnosis.
非 KM Figure
Figure 2Figure 2 Most frequently mutated genes at randomization.
非 KM Figure